Filter By Category
Archives
Share on -
DUVAKITUG
Generic Name: DUVAKITUG
ABSTRACT -
Duvakitug is an investigational anti-TL1A monoclonal antibody being studied in inflammatory bowel disease, including ulcerative colitis and Crohn disease.
DOSAGE -
No approved dosage. Administered per clinical trial protocol; phase studies use protocol-specific parenteral regimens.
SIDE EEFECTS -
- Upper respiratory infection
- Headache
- Injection or infusion reactions
- Abdominal symptoms
- Laboratory abnormalities
ALLERGIC REACTIONS -
(These symptoms may indicate an allergic reaction and require medical attention.)
- Rash or urticaria
- Angioedema
- Bronchospasm
- Anaphylaxis (rare)
DRUG INTERACTIONS-
- Concomitant biologic immunomodulators may increase infection risk
- Corticosteroids/immunosuppressants may alter safety profile
- Avoid live vaccines during therapy
PREAUTONS–
- Screen for infection risk and latent infections per protocol
- Monitor IBD activity and infection signs
- Use only in clinical research until approved
WARNINGS –
- Investigational biologic
- Serious infection and hypersensitivity risks require monitoring
Share on -
. Developed by